DZR123
Sponsors
Novartis Pharma AG
Conditions
Metastatic castrate resistant prostate cancer (mCRPC)Metastatic hormone-sensitive prostate canceradvancedendometrial
carcinomalymphoma including peripheral T-cell Lymphoma and GCBDLBCLmalignant pleural or peritoneal mesotheliomametastatic castration - resistant prostate cancer (mCRPC))or other advanced/metastatic solid tumors
Phase 1
A Phase 1/2 Study of DZR123 (CPI-0209) in Patients with Advanced Solid Tumors and Lymphomas
RecruitingCTIS2023-508002-20-00
Start: 2021-10-21Target: 104Updated: 2025-12-19
TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-label multicenter, Phase II study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients with progressive metastatic castrate resistant prostate cancer
Not yet recruitingCTIS2025-521880-10-00
Target: 76Updated: 2025-12-16
TulmiSTAR-02: A two-part Phase I dose escalation study of tulmimetostat (DZR123) in combination with darolutamide or abiraterone followed by open-label, randomized, Phase II dose expansion study to assess the safety and efficacy of tulmimetostat in combination with darolutamide versus darolutamide alone in patients with metastatic hormone-sensitive prostate cancer
Not yet recruitingCTIS2025-521873-15-00
Target: 54Updated: 2026-01-16